p53 gene therapy (MultiVir)

N/A

Report date: 2024/11/19 20:00:10

Base Information

Drug Namep53 gene therapy (MultiVir)
Drug Alias NameAdenoviral p53-MultiVirAd-p53-MultiVir
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionApoptosis stimulantsTumor protein p53 stimulantsGene transference
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMultivir Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMultivir Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A